UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of May 2024
Commission
File Number: 001-38878
So-Young International Inc.
2/F, East Tower, Poly Plaza, No. 66 Xiangbin Road
Chaoyang District, Beijing, 100012
People's Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F ¨
Exhibit Index
Exhibit 99.1—Press Release
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
So-Young International Inc. |
| |
|
| |
By |
|
/s/ Hui Zhao |
| |
Name |
: |
Hui Zhao |
| |
Title |
: |
Chief Financial Officer |
Date: May 28, 2024
Exhibit 99.1
So-Young
Reports Unaudited First Quarter 2024 Financial Results
BEIJING,
China, May 28, 2024 — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”),
the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry,
today announced its unaudited financial results for the first quarter ended March 31, 2024.
First
Quarter 2024 Financial Highlights
| · | Total revenues were RMB318.3 million (US$44.1 million1),
compared with RMB310.1 million in the corresponding period of 2023, exceeding the high end of guidance. |
| · | Net loss attributable to So-Young International Inc. was RMB21.2 million (US$2.9 million), compared with
net loss attributable to So-Young International Inc. of RMB11.9 million in the same period of 2023. |
| · | Non-GAAP net income attributable to So-Young International Inc.2
was RMB4.1 million (US$0.6 million), compared with non-GAAP net loss attributable to So-Young International Inc. of RMB2.8 million in
the same period of 2023. |
First Quarter 2024 Operational
Highlights
| · | Average mobile MAUs were 2.0 million, compared with 3.4 million in the first quarter of 2023. |
| · | Number of medical service providers subscribing to information services on So-Young’s platform was
1,160, compared with 1,419 in the first quarter of 2023. |
| · | Total number of purchasing users through reservation services was 132.8 thousand and the aggregate value
of medical aesthetic treatment transactions facilitated by So-Young’s platform was RMB367.1
million. |
Mr. Xing Jin, Co-Founder and Chief Executive
Officer of So-Young, commented, “In the first quarter, our business continued to showcase its remarkable resilience and adaptability,
with top line exceeding guidance and increasing 2.6% year-over-year to RMB318.3 million. Growth during the quarter was primarily driven
by sales of medical products and maintenance services, which increased 23.3% year-over-year. More importantly, we made significant progress
in the businesses we are developing to fuel future growth. Building on the success of our model clinic, we are on track to expand our
network into core cities nationwide by the end of the year. With a firm focus on ensuring the quality of products and services, we standardized
operating procedures to streamline every stage from site selection to clinic opening and operations, allowing us to grow our offline presence
at a rapid pace. Directly complimenting this is our supply chain business. With a growing pipeline of products and an expanding distribution
network now covering 750 institutions, we are able to spot emerging trends, quickly bring new high-quality products to market, and create
a win-win outcome for both upstream suppliers and end consumers. We will continue to enhance the vertical integration of our platform
to maximize synergies along the industry value chain. I’m confident these endeavors will create long-term sustainable value for
our users and shareholders going forward.”
1
This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader.
Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.2203
to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States
on March 29, 2024.
2
Non-GAAP net income/(loss) attributable to So-Young International Inc. is defined as net income/(loss) attributable to So-Young International
Inc. excluding share-based compensation expenses attributable to So-Young International Inc. See “Reconciliation of GAAP and Non-GAAP
Results” at the end of this press release.
Mr. Hui Zhao, Chief Financial Officer of
So-Young, added, “Our sales of medical products and maintenance services business made solid progress in the first quarter as it
increasingly contributes to revenue growth and gains traction in the market. Within just a few months, our newly established clinics are
able to outperform our financial models. We will continue investing in and nurturing these promising businesses during their growth phases.
At the same time, we are implementing disciplined cost controls to support a healthy and sustainable expansion of our bottom line.”
First Quarter 2024 Financial Results
Revenues
Total revenues were RMB318.3 million (US$44.1
million), an increase of 2.6% from RMB310.1 million in the same period of 2023. The increase was primarily due to an increase in revenues
generated by the sales of medical products and maintenance services from growing order volumes for cosmetic products and medical equipment.
| · | Information services and other revenues were RMB208.7 million (US$28.9 million), a decrease of
0.7% from RMB210.3 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers
subscribing to information services on So-Young’s platform. |
| · | Reservation services revenues were RMB23.1 million (US$3.2 million), a decrease of 22.3% from
RMB29.7 million in the same period of 2023. The decrease was primarily due to the policy change for commission rates and subsidies. |
| · | Sales of medical products and maintenance services3
were RMB86.5 million (US$12.0 million), an increase of 23.3% from RMB70.1 million in the same period of 2023, primarily due to an increase
in sales of cosmetic products and medical equipment. |
Cost of Revenues4
Cost of revenues was RMB117.3 million (US$16.2
million), an increase of 3.2% from RMB113.7 million in the first quarter of 2023. The increase was primarily due to an increase in costs
associated with the sales of cosmetic products and medical equipment. Cost of revenues included the reversal of share-based compensation
expenses of RMB0.1 million (US$0.0 million), compared with the share-based compensation expenses of RMB0.8 million in the corresponding
period of 2023.
| · | Cost of services and others were RMB74.2 million (US$10.3 million), a decrease of 8.9% from RMB81.5
million in the first quarter of 2023. The decrease was primarily due to a decrease in payroll cost. |
| · | Cost of medical products sold and maintenance services were RMB43.1 million (US$6.0 million), an
increase of 33.7% from RMB32.2 million in the first quarter of 2023. The increase was primarily due to an increase in costs associated
with the sales of cosmetic products and medical equipment. |
3
Since the second quarter of 2023, in light of the better monitoring business development of upstream supply chain, the Company
grouped the revenue generated from sales of cosmetic injectables and sales of equipment and maintenance services into one line item,
which is renamed as sales of medical products and maintenance services.
The
sale of cosmetic injectables was previously reported in line item of information services and others. The information services and others
for the first quarter of 2023 have also been retrospectively updated. The amount reclassified from information services and others
to sales of medical products and maintenance services are RMB7.6 million for the first quarter of 2023.
4
Since the second quarter of 2023, the previous line item cost of revenues was separated into two line items, which are cost of medical
products sold and maintenance services and cost of services and others. Cost of medical products sold and maintenance services primarily
consists of expenditures relating to medical products and maintenance services, and the remaining cost of revenues is reclassified into
cost of services and others. The cost of medical products sold and maintenance services and cost of services and others for the first
quarter of 2023 have also been retrospectively reclassified.
Operating Expenses
Total operating expenses were RMB237.8 million
(US$32.9 million), an increase of 3.5% from RMB229.8 million in the first quarter of 2023.
| · | Sales and marketing expenses were RMB113.3 million (US$15.7 million), an increase of 0.7%
from RMB112.5 million in the first quarter of 2023. The increase was primarily due to an increase in payroll costs associated with the
expansion of marketing employees. Sales and marketing expenses included share-based compensation expenses of RMB0.1 million (US$0.0 million),
compared with RMB1.5 million in the corresponding period of 2023. |
| · | General and administrative expenses were RMB85.0 million (US$11.8 million), an increase of
38.1% from RMB61.5 million in the first quarter of 2023. The increase was due to an increase in payroll costs associated with the expansion
of administrative employees to support our business upgrade and new strategic businesses. General and administrative expenses included
share-based compensation expenses of RMB24.5 million (US$3.4 million), compared with RMB6.0 million in the corresponding period of 2023. |
| · | Research and development expenses were RMB39.6 million (US$5.5 million), a decrease of 29.0%
from RMB55.8 million in the first quarter of 2023. The decrease was primarily attributable to improvements in staff efficiency. Research
and development expenses included share-based compensation expenses of RMB0.8 million (US$0.1 million), compared with RMB0.9 million in
the corresponding period of 2023. |
Income Tax Benefits
Income tax benefits were RMB2.6 million (US$0.4
million), compared with income tax benefits of RMB4.3 million in the same period of 2023.
Net Loss Attributable to So-Young International Inc.
Net
loss attributable to So-Young International Inc. was RMB21.2 million (US$2.9 million), compared with a net loss attributable to
So-Young International Inc. of RMB11.9 million in the first quarter of 2023.
Non-GAAP Net Income/(Loss) Attributable to So-Young International
Inc.
Non-GAAP
net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses attributable
to So-Young International Inc., was RMB4.1 million (US$0.6 million), compared with RMB2.8 million non-GAAP net loss attributable to So-Young
International Inc. in the same period of 2023.
Basic and Diluted Loss per ADS
Basic and diluted loss per ADS attributable to
ordinary shareholders were RMB0.21 (US$0.03) and RMB0.21 (US$0.03), respectively, compared with basic and diluted loss per ADS attributable
to ordinary shareholders of RMB0.12 and RMB0.12, respectively, in the same period of 2023.
Cash and Cash Equivalents, Restricted Cash and Term Deposits,
Term Deposits and Short-Term Investments
As of March 31, 2024, cash and cash equivalents,
restricted cash and term deposits, term deposits and short-term investments were RMB1,345.1 million (US$186.3 million), compared with
RMB1,341.6 million as of December 31, 2023.
Business Outlook
For the second quarter of 2024, So-Young expects
total revenues to be between RMB380.0 million (US$52.6 million) and RMB400.0 million (US$55.4 million), representing a 7.8% to 2.9% decrease
from the same period in 2023. The above outlook is based on the current market conditions and reflects the Company’s preliminary
estimates of market and operating conditions, as well as customer demand, which are all subject to change.
Non-GAAP Financial Measures
To
supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP,
this press release presents non-GAAP income/(loss) from operations and non-GAAP net income/(loss) attributable to So-Young International
Inc. by excluding share-based compensation expenses from income/(loss) from operations and net income/(loss) attributable to So-Young
International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the
Company’s operating and financial performance, compare business trends among different reporting periods on a consistent
basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash
payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will
continue to be incurred in the future. All these are not reflected in the presentation of the non-GAAP financial measures, but should
be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the
relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures,
which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in
addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial
measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable
GAAP financial measure is set forth at the end of this release.
Conference Call Information
So-Young's management will hold an earnings conference
call on Tuesday, May 28, 2024, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for
the earnings conference call are as follows:
| International: |
+1-412-902-4272 |
| Mainland China： |
4001-201203 |
| US: |
+1-888-346-8982 |
| Hong Kong： |
+852-301-84992 |
| Passcode: |
So-Young International Inc. |
A telephone replay will be available two hours
after the conclusion of the conference call through 23:59 U.S. Eastern Time, June 4, 2024. The dial-in details are:
| International: |
+1-412-317-0088 |
| US: |
+1-877-344-7529 |
| Passcode: |
5402361 |
Additionally,
a live and archived webcast of this conference call will be available at http://ir.soyoung.com.
About So-Young International Inc.
So-Young International Inc. (Nasdaq: SY) (“So-Young”
or the “Company”) is the largest and most vibrant social community in China for consumers, professionals and service providers
in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy
content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that
are carefully selected and vetted. Leveraging So-Young’s strong brand image, extensive audience reach, trust from its users, highly
engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value
chain and into the massive, fast-growing consumption healthcare service market.
Safe Harbor Statement
This
announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,”
“expects,” “anticipates,” “future,” “intends,” “plans,” “believes,”
“estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from
management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements.
So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission,
in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors
or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young’s
beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number
of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited
to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations;
So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition
in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies
and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China;
and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the
Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments
is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable
law.
For more information, please contact:
So-Young
Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail: ir@soyoung.com
Christensen
In China
Mr. Julie Zhu
Phone: +86-10-5900-1548
E-mail: julie.zhu@christensencomms.com
In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: linda.bergkamp@christensencomms.com
SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except for share and
per share data)
| | |
As of | |
| | |
December 31, | | |
March 31, | | |
March 31, | |
| | |
2023 | | |
2024 | | |
2024 | |
| | |
RMB | | |
RMB | | |
US$ | |
| Assets | |
| | | |
| | | |
| | |
| Current assets: | |
| | | |
| | | |
| | |
| Cash and cash equivalents | |
| 426,119 | | |
| 448,036 | | |
| 62,052 | |
| Restricted cash and term deposits | |
| 14,695 | | |
| 22,176 | | |
| 3,071 | |
| Trade receivables | |
| 57,219 | | |
| 57,812 | | |
| 8,007 | |
| Inventories | |
| 118,924 | | |
| 126,533 | | |
| 17,525 | |
| Receivables from online payment platforms | |
| 23,158 | | |
| 31,386 | | |
| 4,347 | |
| Amounts due from related parties | |
| 9,212 | | |
| 10,185 | | |
| 1,411 | |
| Term deposits and short-term investments | |
| 900,823 | | |
| 874,890 | | |
| 121,171 | |
| Prepayment and other current assets | |
| 171,774 | | |
| 177,620 | | |
| 24,600 | |
| Total current assets | |
| 1,721,924 | | |
| 1,748,638 | | |
| 242,184 | |
| Non-current assets: | |
| | | |
| | | |
| | |
| Long-term investments | |
| 261,016 | | |
| 256,020 | | |
| 35,458 | |
| Intangible assets | |
| 145,253 | | |
| 139,142 | | |
| 19,271 | |
| Goodwill | |
| 540,693 | | |
| 540,693 | | |
| 74,885 | |
| Property and equipment, net | |
| 116,782 | | |
| 113,159 | | |
| 15,672 | |
| Deferred tax assets | |
| 78,034 | | |
| 79,621 | | |
| 11,027 | |
| Operating lease right-of-use assets | |
| 118,408 | | |
| 122,035 | | |
| 16,902 | |
| Other non-current assets | |
| 232,455 | | |
| 189,442 | | |
| 26,237 | |
| Total non-current assets | |
| 1,492,641 | | |
| 1,440,112 | | |
| 199,452 | |
| Total assets | |
| 3,214,565 | | |
| 3,188,750 | | |
| 441,636 | |
| | |
| | | |
| | | |
| | |
| Liabilities | |
| | | |
| | | |
| | |
| Current liabilities: | |
| | | |
| | | |
| | |
| Dividend payable | |
| — | | |
| 43,573 | | |
| 6,035 | |
| Short-term borrowings | |
| 29,825 | | |
| 29,931 | | |
| 4,145 | |
| Taxes payable | |
| 56,894 | | |
| 56,128 | | |
| 7,774 | |
| Contract liabilities | |
| 103,374 | | |
| 97,798 | | |
| 13,545 | |
| Salary and welfare payables | |
| 86,290 | | |
| 52,662 | | |
| 7,294 | |
| Amounts due to related parties | |
| 388 | | |
| 164 | | |
| 23 | |
| Accrued expenses and other current liabilities | |
| 233,913 | | |
| 237,337 | | |
| 32,868 | |
| Operating lease liabilities-current | |
| 29,739 | | |
| 26,261 | | |
| 3,637 | |
| Total current liabilities | |
| 540,423 | | |
| 543,854 | | |
| 75,321 | |
| Non-current liabilities: | |
| | | |
| | | |
| | |
| Operating lease liabilities-non current | |
| 86,210 | | |
| 95,560 | | |
| 13,235 | |
| Deferred tax liabilities | |
| 25,082 | | |
| 23,356 | | |
| 3,235 | |
| Other non-current liabilities | |
| 1,536 | | |
| 1,855 | | |
| 257 | |
| Total non-current liabilities | |
| 112,828 | | |
| 120,771 | | |
| 16,727 | |
| Total liabilities | |
| 653,251 | | |
| 664,625 | | |
| 92,048 | |
SO-YOUNG INTERNATIONAL INC.
UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)
(Amounts in thousands, except for share and
per share data)
| Shareholders’ equity: | |
| | | |
| | | |
| | |
| Treasury stock | |
| (358,453 | ) | |
| (359,089 | ) | |
| (49,733 | ) |
| Class A ordinary shares (US$0.0005 par value; 750,000,000 shares authorized as of December 31, 2023 and March 31, 2024; 73,688,044 and 63,422,436 shares issued and outstanding as of December 31, 2023, 77,010,327 and 66,679,778 shares issued and outstanding as of March 31, 2024, respectively) | |
| 238 | | |
| 250 | | |
| 35 | |
| Class B ordinary shares (US$ 0.0005 par value; 20,000,000 shares authorized as of December 31, 2023 and March 31, 2024; 12,000,000 shares issued and outstanding as of December 31, 2023 and March 31, 2024) | |
| 37 | | |
| 37 | | |
| 5 | |
| Additional paid-in capital | |
| 3,080,433 | | |
| 3,062,378 | | |
| 424,134 | |
| Statutory reserves | |
| 33,855 | | |
| 33,855 | | |
| 4,689 | |
| Accumulated deficit | |
| (330,166 | ) | |
| (351,406 | ) | |
| (48,669 | ) |
| Accumulated other comprehensive income | |
| 18,185 | | |
| 19,861 | | |
| 2,751 | |
| Total So-Young International Inc. shareholders’ equity | |
| 2,444,129 | | |
| 2,405,886 | | |
| 333,212 | |
| Non-controlling interests | |
| 117,185 | | |
| 118,239 | | |
| 16,376 | |
| Total shareholders’ equity | |
| 2,561,314 | | |
| 2,524,125 | | |
| 349,588 | |
| Total liabilities and shareholders’ equity | |
| 3,214,565 | | |
| 3,188,750 | | |
| 441,636 | |
SO-YOUNG INTERNATIONAL
INC.
UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(Amounts in thousands,
except for share and per share data)
| | |
For the Three Months Ended | |
| | |
March 31,
2023 | | |
December 31, 2023 | | |
March 31, 2024 | | |
March 31, 2024 | |
| | |
RMB | | |
RMB | | |
RMB | | |
US$ | |
| Revenues: | |
| | | |
| | | |
| | | |
| | |
| Information services and others | |
| 210,284 | | |
| 268,078 | | |
| 208,748 | | |
| 28,911 | |
| Reservation services | |
| 29,681 | | |
| 20,589 | | |
| 23,064 | | |
| 3,194 | |
| Sales of medical products and maintenance services | |
| 70,138 | | |
| 101,899 | | |
| 86,470 | | |
| 11,976 | |
| Total revenues | |
| 310,103 | | |
| 390,566 | | |
| 318,282 | | |
| 44,081 | |
| Cost of revenues: | |
| | | |
| | | |
| | | |
| | |
| Cost of services and others | |
| (81,500 | ) | |
| (94,079 | ) | |
| (74,222 | ) | |
| (10,280 | ) |
| Cost of medical products sold and maintenance services | |
| (32,221 | ) | |
| (43,555 | ) | |
| (43,093 | ) | |
| (5,968 | ) |
| Total cost of revenues | |
| (113,721 | ) | |
| (137,634 | ) | |
| (117,315 | ) | |
| (16,248 | ) |
| Gross profit | |
| 196,382 | | |
| 252,932 | | |
| 200,967 | | |
| 27,833 | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| Sales and marketing expenses | |
| (112,511 | ) | |
| (126,175 | ) | |
| (113,256 | ) | |
| (15,686 | ) |
| General and administrative expenses | |
| (61,514 | ) | |
| (86,668 | ) | |
| (84,953 | ) | |
| (11,766 | ) |
| Research and development expenses | |
| (55,793 | ) | |
| (44,993 | ) | |
| (39,591 | ) | |
| (5,483 | ) |
| Total operating expenses | |
| (229,818 | ) | |
| (257,836 | ) | |
| (237,800 | ) | |
| (32,935 | ) |
| Loss from operations | |
| (33,436 | ) | |
| (4,904 | ) | |
| (36,833 | ) | |
| (5,102 | ) |
| Other income/(expenses): | |
| | | |
| | | |
| | | |
| | |
| Investment income, net | |
| 6,852 | | |
| 1,135 | | |
| 2,099 | | |
| 291 | |
| Interest income, net | |
| 11,927 | | |
| 10,820 | | |
| 12,313 | | |
| 1,705 | |
| Exchange gains | |
| 425 | | |
| 389 | | |
| 394 | | |
| 55 | |
| Impairment of long-term investment | |
| — | | |
| (444 | ) | |
| — | | |
| — | |
| Share of losses of equity method investee | |
| (3,171 | ) | |
| (2,031 | ) | |
| (3,996 | ) | |
| (553 | ) |
| Others, net | |
| 2,025 | | |
| 3,424 | | |
| 3,280 | | |
| 454 | |
| (Loss)/income before tax | |
| (15,378 | ) | |
| 8,389 | | |
| (22,743 | ) | |
| (3,150 | ) |
| Income tax benefits | |
| 4,264 | | |
| 10,835 | | |
| 2,557 | | |
| 354 | |
| Net (loss)/income | |
| (11,114 | ) | |
| 19,224 | | |
| (20,186 | ) | |
| (2,796 | ) |
| Net income attributable to noncontrolling interests | |
| (834 | ) | |
| (1,723 | ) | |
| (1,054 | ) | |
| (146 | ) |
| Net (loss)/income attributable to So-Young International Inc. | |
| (11,948 | ) | |
| 17,501 | | |
| (21,240 | ) | |
| (2,942 | ) |
SO-YOUNG INTERNATIONAL
INC.
UNAUDITED CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS (Continued)
(Amounts in thousands,
except for share and per share data)
| | |
For the Three Months Ended | |
| | |
March 31,
2023 | | |
December 31, 2023 | | |
March 31, 2024 | | |
March 31, 2024 | |
| | |
RMB | | |
RMB | | |
RMB | | |
US$ | |
| Net (loss)/earnings per ordinary share | |
| | | |
| | | |
| | | |
| | |
| Net (loss)/earnings per ordinary share attributable to ordinary shareholder - basic | |
| (0.15 | ) | |
| 0.23 | | |
| (0.27 | ) | |
| (0.04 | ) |
| Net (loss)/earnings per ordinary share attributable to ordinary shareholder - diluted | |
| (0.15 | ) | |
| 0.23 | | |
| (0.27 | ) | |
| (0.04 | ) |
| Net (loss)/earnings per ADS attributable to ordinary shareholders - basic (13 ADS represents 10 Class A ordinary shares) | |
| (0.12 | ) | |
| 0.18 | | |
| (0.21 | ) | |
| (0.03 | ) |
| Net (loss)/earnings per ADS attributable to ordinary shareholders - diluted (13 ADS represents 10 Class A ordinary shares) | |
| (0.12 | ) | |
| 0.18 | | |
| (0.21 | ) | |
| (0.03 | ) |
| Weighted average number of ordinary shares used in computing earnings/(loss) per share, basic* | |
| 79,850,312 | | |
| 76,584,151 | | |
| 79,551,454 | | |
| 79,551,454 | |
| Weighted average number of ordinary shares used in computing earnings/(loss) per share, diluted* | |
| 79,850,312 | | |
| 77,011,890 | | |
| 79,551,454 | | |
| 79,551,454 | |
| | |
| | | |
| | | |
| | | |
| | |
| Share-based compensation expenses included in: | |
| | | |
| | | |
| | | |
| | |
| Cost of revenues | |
| (805 | ) | |
| (165 | ) | |
| 55 | | |
| 8 | |
| Sales and marketing expenses | |
| (1,494 | ) | |
| (2,830 | ) | |
| (53 | ) | |
| (7 | ) |
| General and administrative expenses | |
| (6,018 | ) | |
| (13,190 | ) | |
| (24,453 | ) | |
| (3,387 | ) |
| Research and development expenses | |
| (877 | ) | |
| (1,615 | ) | |
| (843 | ) | |
| (117 | ) |
| * | Both Class A and Class B ordinary shares are included in the calculation of the weighted average
number of ordinary shares outstanding, basic and diluted. |
SO-YOUNG INTERNATIONAL INC.
Reconciliation of GAAP and Non-GAAP Results
(Amounts in thousands, except for share and
per share data)
| | |
For the Three Months Ended | |
| | |
March 31,
2023 | | |
December 31, 2023 | | |
March 31, 2024 | | |
March 31, 2024 | |
| | |
RMB | | |
RMB | | |
RMB | | |
US$ | |
| GAAP loss from operations | |
| (33,436 | ) | |
| (4,904 | ) | |
| (36,833 | ) | |
| (5,102 | ) |
| Add back: Share-based compensation expenses | |
| 9,194 | | |
| 17,800 | | |
| 25,294 | | |
| 3,503 | |
| Non-GAAP (loss)/income from operations | |
| (24,242 | ) | |
| 12,896 | | |
| (11,539 | ) | |
| (1,599 | ) |
| | |
| | | |
| | | |
| | | |
| | |
| GAAP net (loss)/income attributable to So-Young International Inc. | |
| (11,948 | ) | |
| 17,501 | | |
| (21,240 | ) | |
| (2,942 | ) |
| Add back: Share-based compensation expenses | |
| 9,194 | | |
| 17,800 | | |
| 25,294 | | |
| 3,503 | |
| Non-GAAP net (loss)/income attributable to So-Young International Inc. | |
| (2,754 | ) | |
| 35,301 | | |
| 4,054 | | |
| 561 | |
So Young (NASDAQ:SY)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
So Young (NASDAQ:SY)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
